查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589461

糖尿病相關眼部治療市場：按產品類型、應用和最終用途分類－2025-2030 年全球預測

Diabetes Associated Ophthalmic Treatment Market by Product Type (Devices, Drugs), Application (Cataract, Diabetic associated Macular Degeneration, Diabetic Macular Edema), End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，糖尿病相關眼科保健市場價值為57.1億美元，預計2024年將達到61.8億美元，複合年成長率為8.59%，預計到2030年將達到101.8億美元。

與糖尿病相關的眼部護理包括用於管理和緩解糖尿病引起的眼部相關併發症（例如糖尿病視網膜病變和糖尿病黃斑部水腫）的醫療干預措施和產品。隨著全球糖尿病盛行率的不斷上升，導致相關眼科疾病的增加，這一領域至關重要。應用涵蓋為糖尿病患者量身定做的診斷、治療和監測技術。主要最終用戶包括醫院、診所和眼科專科中心。推動該市場的主要成長要素包括糖尿病人口的增加、醫療技術的進步以及醫療保健支出的增加。成長機會包括人工智慧在診斷中的整合、新藥物輸送系統的開發以及成像技術的增強，為公司提供了重要的成長途徑。對相關人員的建議包括投資於研發以創新具有更高功效和患者依從性的產品，利用策略夥伴關係進行技術整合，以及增加糖尿病患者的數量，其中包括擴展到新興市場。

主要市場統計
基準年[2023] 57.1億美元
預測年份 [2024] 61.8億美元
預測年份 [2030] 101.8億美元
複合年成長率（%） 8.59%

然而，市場限制包括先進治療和技術的高成本可能會限制低收入者的使用，以及監管要求的複雜性導致產品上市延遲。新興國家面臨醫療基礎設施不足的挑戰，影響了市場滲透率。創新將針對具有成本效益的治療解決方案、偏遠和服務不足地區的攜帶式診斷設備以及個人化醫療。趨勢表明，作為影響患者管理的數位健康方面，精準醫療和遠距眼科的趨勢不斷成長。市場的本質是動態和競爭的，頻繁的技術進步和策略聯盟是產業成功的重要組成部分。公司保持適應性，專注於產品本地化以滿足不同的監管和患者需求，透過環保實踐確保永續性，並改善與糖尿病相關的眼部併發症的早期檢測和管理，必須優先考慮患者的教育。

市場動態：快速發展的糖尿病相關眼科治療市場的關鍵市場洞察

供需的動態交互作用正在改變與糖尿病相關的眼部保健市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 老年人口增加導致糖尿病盛行率增加
    • 人們越來越傾向早期診斷糖尿病
    • 提高與糖尿病眼疾相關的認知舉措
  • 市場限制因素
    • 缺乏熟練且知識淵博的眼科醫生
  • 市場機會
    • 活性化研發活動以開發先進的糖尿病眼部治療方法
    • 糖尿病相關眼部治療設備的巨大潛力
  • 市場挑戰
    • 糖尿病相關眼部治療藥物的核准期限

波特五力：駕馭糖尿病相關眼科治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解糖尿病相關眼科治療市場的外部影響

外部宏觀環境因素在塑造糖尿病相關眼部保健市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解糖尿病相關眼科治療市場的競爭狀況

對糖尿病相關眼科治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣糖尿病相關眼部治療市場供應商的績效評估

FPNV定位矩陣是評估糖尿病相關眼部保健市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為糖尿病相關眼部治療市場的成功指明道路

對於旨在加強其在全球市場的影響力的公司來說，對糖尿病相關眼科治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著人口老化的加劇，糖尿病的發生率也隨之增加
      • 糖尿病早期診斷的趨勢日益成長
      • 加強提高人們對糖尿病眼疾的認知
    • 抑制因素
      • 缺乏熟練且知識淵博的眼科醫生
    • 機會
      • 活性化旨在開發與糖尿病相關的先進眼科治療方法的研發活動
      • 糖尿病相關眼部治療設備的巨大潛力
    • 任務
      • 糖尿病相關眼部治療藥物核准週期長
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章糖尿病相關眼科治療市場：依產品類型

  • 裝置
  • 藥品

第7章 糖尿病相關眼科治療市場：依應用分類

  • 白內障
  • 糖尿病黃斑部病變
  • 糖尿病黃斑部水腫
  • 糖尿病視網膜病變
  • 乾眼症
  • 眼睛過敏和感染疾病
  • 青光眼
  • 葡萄膜炎

第8章糖尿病相關眼科治療市場：依最終用途分類

  • 門診手術中心
  • 醫院
  • 眼科中心

第9章北美及南美糖尿病相關眼部保健市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區糖尿病相關眼科治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲糖尿病相關眼科治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Adverum Biotechnologies, Inc.
  • Alimera Sciences, Inc.
  • Allergan PLC
  • Ampio Pharmaceuticals, Inc.
  • Apexian Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated.
  • Bayer AG
  • Eisai Co Ltd.
  • Graybug Vision Inc.
  • Kalvista Pharmaceuticals Ltd.
  • Kodiak Sciences Inc.
  • Kubota Vision Inc.
  • Novartis AG
  • Ocuphire Pharma, Inc.
  • Regeneron Pharmaceuticals Inc.
Product Code: MRR-563BF1FCF469

The Diabetes Associated Ophthalmic Treatment Market was valued at USD 5.71 billion in 2023, expected to reach USD 6.18 billion in 2024, and is projected to grow at a CAGR of 8.59%, to USD 10.18 billion by 2030.

The scope of diabetes-associated ophthalmic treatment encompasses a range of medical interventions and products designed to manage and mitigate eye-related complications stemming from diabetes, such as diabetic retinopathy and diabetic macular edema. This sector is crucial due to the increasing prevalence of diabetes globally, which leads to a rise in associated ocular disorders. The application extends across diagnostics, therapeutics, and monitoring technologies tailored for diabetic patients. The primary end-users include hospitals, clinics, and specialized ophthalmic centers. Key growth factors driving this market include the growing diabetic population, advancements in medical technology, and increased healthcare expenditure. Opportunities arise from the integration of AI in diagnostics, development of novel drug delivery systems, and enhanced imaging technologies, providing companies avenues for substantial growth. Recommendation for stakeholders involves investing in R&D to innovate products with better efficacy and patient compliance, leveraging strategic partnerships for technology integration, and expanding into emerging markets with growing diabetic incidences.

KEY MARKET STATISTICS
Base Year [2023] USD 5.71 billion
Estimated Year [2024] USD 6.18 billion
Forecast Year [2030] USD 10.18 billion
CAGR (%) 8.59%

However, market limitations include the high cost of advanced treatments and technologies, which may restrict access for lower-income groups, and the complexity of regulatory requirements that can delay product launches. Emerging economies face challenges with inadequate healthcare infrastructure, affecting market penetration. Innovation can be directed towards cost-effective treatment solutions, portable diagnostic devices for remote and underserved locations, and personalized medicine. Insights indicate an increasing trend towards precision medicine and teleophthalmology as facets of digital health influencing patient management. The nature of the market is dynamic and competitive, with frequent technological advancements and strategic collaborations forming an integral part of industry success. Businesses must remain adaptable, focusing on localization of products to meet diverse regulatory and patient needs, ensuring sustainability through eco-friendly practices, and prioritizing patient education on early detection and management of diabetes-related eye complications.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetes Associated Ophthalmic Treatment Market

The Diabetes Associated Ophthalmic Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of diabetes with rising geriatric population
    • Growing inclination towards early diagnosis of diabetes
    • Rising number of initiatives to increase awareness associated diabetes ophthalmic disease
  • Market Restraints
    • Lack of skilled and knowledgeable ophthalmologists
  • Market Opportunities
    • Rising R&D activities to develop advanced diabetes associated ophthalmic treatments
    • High potential for diabetes associated ophthalmic treatment devices
  • Market Challenges
    • Long duration of drug approvals for diabetes associated ophthalmic treatment

Porter's Five Forces: A Strategic Tool for Navigating the Diabetes Associated Ophthalmic Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetes Associated Ophthalmic Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetes Associated Ophthalmic Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetes Associated Ophthalmic Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetes Associated Ophthalmic Treatment Market

A detailed market share analysis in the Diabetes Associated Ophthalmic Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetes Associated Ophthalmic Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetes Associated Ophthalmic Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetes Associated Ophthalmic Treatment Market

A strategic analysis of the Diabetes Associated Ophthalmic Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetes Associated Ophthalmic Treatment Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., Alimera Sciences, Inc., Allergan PLC, Ampio Pharmaceuticals, Inc., Apexian Pharmaceuticals, Inc., Bausch & Lomb Incorporated., Bayer AG, Eisai Co Ltd., Graybug Vision Inc., Kalvista Pharmaceuticals Ltd., Kodiak Sciences Inc., Kubota Vision Inc., Novartis AG, Ocuphire Pharma, Inc., and Regeneron Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Diabetes Associated Ophthalmic Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Devices and Drugs.
  • Based on Application, market is studied across Cataract, Diabetic associated Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye Syndrome, Eye Allergy & Infection, Glaucoma, and Uveitis.
  • Based on End-use, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmic Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diabetes with rising geriatric population
      • 5.1.1.2. Growing inclination towards early diagnosis of diabetes
      • 5.1.1.3. Rising number of initiatives to increase awareness associated diabetes ophthalmic disease
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of skilled and knowledgeable ophthalmologists
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising R&D activities to develop advanced diabetes associated ophthalmic treatments
      • 5.1.3.2. High potential for diabetes associated ophthalmic treatment devices
    • 5.1.4. Challenges
      • 5.1.4.1. Long duration of drug approvals for diabetes associated ophthalmic treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetes Associated Ophthalmic Treatment Market, by Product Type

  • 6.1. Introduction
  • 6.2. Devices
  • 6.3. Drugs

7. Diabetes Associated Ophthalmic Treatment Market, by Application

  • 7.1. Introduction
  • 7.2. Cataract
  • 7.3. Diabetic associated Macular Degeneration
  • 7.4. Diabetic Macular Edema
  • 7.5. Diabetic Retinopathy
  • 7.6. Dry Eye Syndrome
  • 7.7. Eye Allergy & Infection
  • 7.8. Glaucoma
  • 7.9. Uveitis

8. Diabetes Associated Ophthalmic Treatment Market, by End-use

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Ophthalmic Centers

9. Americas Diabetes Associated Ophthalmic Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diabetes Associated Ophthalmic Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diabetes Associated Ophthalmic Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adverum Biotechnologies, Inc.
  • 2. Alimera Sciences, Inc.
  • 3. Allergan PLC
  • 4. Ampio Pharmaceuticals, Inc.
  • 5. Apexian Pharmaceuticals, Inc.
  • 6. Bausch & Lomb Incorporated.
  • 7. Bayer AG
  • 8. Eisai Co Ltd.
  • 9. Graybug Vision Inc.
  • 10. Kalvista Pharmaceuticals Ltd.
  • 11. Kodiak Sciences Inc.
  • 12. Kubota Vision Inc.
  • 13. Novartis AG
  • 14. Ocuphire Pharma, Inc.
  • 15. Regeneron Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CATARACT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC ASSOCIATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRY EYE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY EYE ALLERGY & INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY UVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY OPHTHALMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 150. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023